The Targeted Eradication: Handbook of HER2-Targeted Agents in Breast Cancer
Thirty years ago, a breast cancer diagnosis with a HER2 amplification was an absolute, rapid death sentence; the tumor was violently aggressive and ignored standard chemotherapy. Today, thanks to a revolution in monoclonal antibodies, it is one of the most highly curable subtypes. Handbook of HER2-Targeted Agents in Breast Cancer is a fiercely specialized, highly pharmacological manual detailing exactly how this revolution was engineered. This volume provides the precise molecular blueprints required to weaponize these targeted agents against the HER2 receptor.
Mastering the Dual Blockade
The core philosophy of this text is total receptor shutdown. The authors aggressively detail the mechanics of the Pertuzumab/Trastuzumab combination. It dictates exactly how prescribing a single antibody is no longer enough; the oncologist must fire two different antibodies simultaneously to physically lock onto two different sides of the HER2 receptor, completely paralyzing the tumor’s ability to communicate with the rest of the body.
Navigating Cardiotoxicity
The book provides a masterclass in managing the lethal side effect. It dictates the exact clinical pathways for cardiac preservation. It rigorously explores the terrifying reality that the exact same HER2 receptors targeted on the breast tumor also exist on the patient’s heart muscle, demanding meticulous echocardiogram monitoring to ensure the life-saving cancer drug does not plunge the patient into irreversible congestive heart failure.
Frequently Asked Questions (FAQs)
Does this book cover estrogen-receptor positive or triple-negative breast cancer?
No, its absolute, exclusive focus is on the *pharmacology, molecular biology, and clinical application* of drugs specifically designed for the HER2-amplified subtype.
Who is the primary audience?
It is the absolute, mandatory definitive reference for Medical Oncologists, Oncology Pharmacists, Breast Surgeons, and Translational Researchers.
